Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
G-Pen
- Development stage
- Phase 3
- Lead developer
- Xeris Biopharma
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
G-Pen is a stable liquid glucagon injection developed by Xeris Pharmaceuticals. It is designed for the rescue of hypoglycemia, particularly in adult and pediatric patients with type 1 diabetes. The drug is administered via subcutaneous injection and works by raising blood glucose levels to counteract insulin-induced hypoglycemia. Clinical trials have evaluated its safety and efficacy compared to other glucagon formulations like Lilly Glucagon and Novo Glucagon.
- Brand names
- G-PenG-Pen Mini
- Other names
- G-Pen (glucagon injection)G-Pen™ glucagon
02
Targets
GCGR (Glucagon receptor)
Beyond the preview
Go deeper on G-Pen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on G-Pen.